UK-based, Dxcover (previously Clinspec Diagnostics) is a clinical-stage diagnostics company. The startup has developed a liquid biopsy platform - powered by “attenuated total reflectance, fourier transform infrared spectroscopy” “of pan-omic biomarkers” - which analyzes patient blood samples (with the help of AI) to detect the presence (or absence) of cancer. It generates compelling clinical data with high accuracy detection (80-90%) of Stage I & II brain tumors, particularly Glioblastoma Multiforme (the most aggressive type). The firm has also published data with “exceptional potential” on detecting pancreatic cancer as well as 6 other types (lung, colon, breast, prostate, ovarian & kidney) (the 8-types combined, account for 65% of the global cancer burden). Various patents have already...

Every known method of shipping hydrogen (H2) has its drawbacks: i) Compressed H2 has very low energy density by volume, ii) Liquid H2 requires storage at temperatures of -253°C, iii) Ammonia as well as methanol (which can be decomposed/ cracked over a catalyst to produce H2) have higher volumetric energy density, but the former is extremely toxic & the latter costly to produce, iv) Liquid Organic Hydrogen Carriers (LOHC) (from fossil fuels) require (energy-intensive) high-temperatures to release the H2 (upon delivery). So, what if there was a way of storing hydrogen in a low-cost, non-toxic, non-explosive substance, that is a liquid at ambient temperatures & pressures and requires no energy – only the addition of...